Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Decatur Memorial Hospital
mi
from
Decatur, IL
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Ingalls Memorial Hospital
mi
from
Harvey, IL
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Decitabine in Treating Patients With Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
LDS Hospital
mi
from
Salt Lake City, UT
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
LDS Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
VA Puget Sound Health Care System
mi
from
Seattle, WA
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
University of Torino
mi
from
Torino,
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
University of Torino
mi
from
Torino,
Click here to add this to my saved trials
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
Tandem High-Dose Therapy With Melphalan and Total Marrow Irradiation (TMI) With Peripheral Blood Progenitor Cell Support and Lenalidomide Maintenance in Multiple Myeloma: A Phase I/II Trial
Status: Enrolling
Updated:  12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
Tandem High-Dose Therapy With Melphalan and Total Marrow Irradiation (TMI) With Peripheral Blood Progenitor Cell Support and Lenalidomide Maintenance in Multiple Myeloma: A Phase I/II Trial
Status: Enrolling
Updated: 12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients With Advanced AML or High Risk Myelodysplastic Syndrome
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients With Advanced AML or High Risk Myelodysplastic Syndrome
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
A Phase II Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
A Phase II Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Stem Cell Transplant for Hemoglobinopathy
Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism
Status: Enrolling
Updated:  12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Stem Cell Transplant for Hemoglobinopathy
Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism
Status: Enrolling
Updated: 12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Stem Cell Transplant for Hematological Malignancy
Allogeneic Transplant for Hematological Malignancy
Status: Enrolling
Updated:  12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Stem Cell Transplant for Hematological Malignancy
Allogeneic Transplant for Hematological Malignancy
Status: Enrolling
Updated: 12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia
A Randomized Multicenter Trial of Antenatal Treatment of Alloimmune Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia
A Randomized Multicenter Trial of Antenatal Treatment of Alloimmune Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
New York Blood Center National Cord Blood Program
New York Blood Center National Cord Blood Program
Status: Enrolling
Updated:  12/31/1969
New York Blood Center
mi
from
New York, NY
New York Blood Center National Cord Blood Program
New York Blood Center National Cord Blood Program
Status: Enrolling
Updated: 12/31/1969
New York Blood Center
mi
from
New York, NY
Click here to add this to my saved trials
Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers
Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients With Hematologic Disorders and Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
Department of Veterans Affairs, South Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital Division
mi
from
San Antonio, TX
Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers
Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients With Hematologic Disorders and Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
Department of Veterans Affairs, South Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital Division
mi
from
San Antonio, TX
Click here to add this to my saved trials
Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers
Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients With Hematologic Disorders and Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers
Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients With Hematologic Disorders and Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Dasatinib in Patients With Chronic Myelogenous Leukemia
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib (BMS-354825)
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Dasatinib in Patients With Chronic Myelogenous Leukemia
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib (BMS-354825)
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  12/31/1969
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 12/31/1969
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  12/31/1969
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 12/31/1969
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  12/31/1969
Memoral Sloan Kettering Cancer Center@Phelps
mi
from
Sleepy Hollow, NY
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 12/31/1969
Memoral Sloan Kettering Cancer Center@Phelps
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  12/31/1969
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 12/31/1969
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Randomized Study of Sulindac in Oral Premalignant Lesions
A Pilot Multi-Center International Double-Blind Placebo Controlled Randomized Study of Sulindac, a Pan-Cox Inhibitor, in Oral Premalignant Lesions
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Randomized Study of Sulindac in Oral Premalignant Lesions
A Pilot Multi-Center International Double-Blind Placebo Controlled Randomized Study of Sulindac, a Pan-Cox Inhibitor, in Oral Premalignant Lesions
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Randomized Study of Sulindac in Oral Premalignant Lesions
A Pilot Multi-Center International Double-Blind Placebo Controlled Randomized Study of Sulindac, a Pan-Cox Inhibitor, in Oral Premalignant Lesions
Status: Enrolling
Updated:  12/31/1969
Amrita Institute of Sciences (AIMS)
mi
from
Cochin,
A Randomized Study of Sulindac in Oral Premalignant Lesions
A Pilot Multi-Center International Double-Blind Placebo Controlled Randomized Study of Sulindac, a Pan-Cox Inhibitor, in Oral Premalignant Lesions
Status: Enrolling
Updated: 12/31/1969
Amrita Institute of Sciences (AIMS)
mi
from
Cochin,
Click here to add this to my saved trials
Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia
Multicenter Study of Tibial Dysplasia in Neurofibromatosis Type I (NF1) Patients
Status: Enrolling
Updated:  12/31/1969
Shriners Hospitals for Children, Intermountain Hospital
mi
from
Salt Lake City, UT
Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia
Multicenter Study of Tibial Dysplasia in Neurofibromatosis Type I (NF1) Patients
Status: Enrolling
Updated: 12/31/1969
Shriners Hospitals for Children, Intermountain Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Status: Enrolling
Updated:  12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Status: Enrolling
Updated: 12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen
Status: Enrolling
Updated:  12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen
Status: Enrolling
Updated: 12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen
Status: Enrolling
Updated:  12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen
Status: Enrolling
Updated: 12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
Expression of the Genome in Lymphoid Malignancies
Status: Enrolling
Updated:  12/31/1969
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
Expression of the Genome in Lymphoid Malignancies
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath)
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath)
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
HLA Matched Related and Unrelated Bone Marrow Transplantation With Busulfan/Cyclophosphamide and Post Transplantation Cyclophosphamide for Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
HLA Matched Related and Unrelated Bone Marrow Transplantation With Busulfan/Cyclophosphamide and Post Transplantation Cyclophosphamide for Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Autologous Transplant for Multiple Myeloma
Autologous Transplantation for Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Autologous Transplant for Multiple Myeloma
Autologous Transplantation for Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials